Galmed Pharmaceuticals Ltd (GLMD)

4.17 +0.40  +10.61% NASDAQ Nov 27, 20:00 USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
03/12/2021 Earnings Galmed Pharmaceuticals Ltd Fourth Quarter Earnings for 2020 Release
03/12/2021 Misc Galmed Pharmaceuticals Ltd Fourth Quarter Earnings Conference Call for 2020
11/12/2020 Earnings Galmed Pharmaceuticals Ltd Third Quarter Earnings Result for 2020
11/12/2020 08:30 EST Misc Galmed Pharmaceuticals Ltd Third Quarter Earnings Conference Call for 2020
08/06/2020 08:30 EDT Misc Galmed Pharmaceuticals Ltd Second Quarter Earnings Conference Call for 2020
08/06/2020 Earnings Galmed Pharmaceuticals Ltd Second Quarter Earnings Result for 2020
05/14/2020 08:30 EDT Misc Galmed Pharmaceuticals Ltd First Quarter Earnings Conference Call for 2020
05/14/2020 Earnings Galmed Pharmaceuticals Ltd First Quarter Earnings Result for 2020
03/12/2020 08:30 EDT Misc Galmed Pharmaceuticals Ltd Fourth Quarter Earnings Conference Call for 2019
03/12/2020 Earnings Galmed Pharmaceuticals Ltd Fourth Quarter Earnings in 2019 Release
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.galmedpharma.com
  • Investor Relations URL: http://galmedpharma.investorroom.com/
  • HQ State/Province: N/A
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Growth
  • Next Earnings Release: Mar. 12, 2021
  • Last Earnings Release: Nov. 12, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.